Tenable Holdingsの空売り状況は、投資家がTenable Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Tenable Holdings (NASDAQ:TENB) 株価情報, 空売り情報

Tenable Holdings

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

Tenable Holdings Inc

Teucrium has introduced a <a href="https://www.benzinga.com/etfs">new addition to its ETF suite</a>, the Yields For You Strategy A ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YFYA#NYSE">YFYA</a>). 
Launched on Jan. 31, this fund aims to achieve strong returns while preserving capital. It also has room for capital appreciation, making it a noteworthy investment option for investors seeking stability and growth.
Operating as a fund of funds, YFYA primarily invests in other ETFs that cover various fixed income securities like investment-grade bonds, floating-rate loans, foreign debt securities, and cash equivalents. The ETF carries a net expense ratio of 1.16%.
Also Read: <a href="https://www.benzinga.com/general/market-summary/25/01/43406160/qqqi-how-im-preparing-for-volatility-in-2025">QQQI: How I&#8217;m Preparing for Volatility in 2025</a>
The fund generally holds a set of allocations duration of one year or less, though this can shift based on prevailing market conditions. The ETF does not have strict maturity or duration requirements, allowing for flexibility in its asset allocation.
Beyond fixed income exposure, YFYA also includes a smaller set of equity-focused ETFs, particularly those emphasizing preferred stocks from large and mid-cap companies. 
To hedge against interest rate or market volatility, the fund uses equity-related derivatives. This adaptive strategy makes YFYA suitable for investors looking for a combination of yield and protection amid market uncertainty. The fund's active management provides both offensive and defensive benefits. Its focus on risk management allows the fund to serve as a strong core holding for portfolios requiring stability alongside returns.
With YFYA now part of its offering, Teucrium has expanded its ETF count to 10. <a href="https://www.benzinga.com/etfs/new-etfs/25/01/43010401/maximize-growth-minimize-risk-with-new-dynamic-allocation-etf">One of its notable launches earlier</a> this year, the Relative Strength Managed Volatility Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSMV#NYSE">RSMV</a>), has already surpassed $125 million in assets under management.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43403716/3-u-s-auto-etfs-caught-in-the-crosshairs-as-trump-announces-25-tariff-on-mexican-imports">3 U.S. Auto ETFs Caught In The Crosshairs As Trump Announces 25% Tariff On Mexican Imports</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

RSMV

YFYA

Teucrium Expands ETF Offerings with Yields For You Strategy A ETF

Wells Fargo analyst Michael Sison maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Overweight and lowers the price target from $95 to $90.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on LyondellBasell Industries, Lowers Price Target to $90

Macro Economic Events

Global

Economics

Mexican President Sheinbaum Says Will Work Together With U.S. Going Forward On Security And Trade; She Will Always Support And Defend Mexican Migrants; Says She And Trump Agreed To Maintain Dialogue, No Meeting Scheduled

Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 10 years by 5.34% on an annualized basis producing an average annual return of 16.51%. Currently, Arch Capital Group has a market capitalization of $34.87 billion. 
Buying $1000 In ACGL: If an investor had bought $1000 of ACGL stock 10 years ago, it would be worth $4,652.33 today based on a price of $92.69 for ACGL at the time of writing.
<h3>Arch Capital Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738597557_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ACGL

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Investors with a lot of money to spend have taken a bearish stance on Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HIMS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 22 uncommon options trades for Hims &amp; Hers Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 59%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $867,464, and 14 are calls, for a total amount of $1,137,344.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $55.0 for Hims &amp; Hers Health over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Hims &amp; Hers Health options trades today is 1558.53 with a total volume of 6,140.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Hims &amp; Hers Health's big money trades within a strike price range of $20.0 to $55.0 over the last 30 days.
<h3>Hims &amp; Hers Health Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738597556_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$11.15</td>
<td>$10.5</td>
<td>$11.15</td>
<td>$32.00</td>
<td>$559.9K</td>
<td>588</td>
<td>500</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$5.25</td>
<td>$5.1</td>
<td>$5.1</td>
<td>$40.00</td>
<td>$219.3K</td>
<td>16</td>
<td>1.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$5.25</td>
<td>$5.1</td>
<td>$5.1</td>
<td>$40.00</td>
<td>$147.9K</td>
<td>16</td>
<td>1.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$5.1</td>
<td>$4.45</td>
<td>$5.1</td>
<td>$40.00</td>
<td>$139.7K</td>
<td>16</td>
<td>882</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$2.3</td>
<td>$2.1</td>
<td>$2.3</td>
<td>$37.00</td>
<td>$138.0K</td>
<td>4.2K</td>
<td>58</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
In light of the recent options history for Hims &amp; Hers Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Hims &amp; Hers Health</h3>
<ul>
<li>Currently trading with a volume of 5,022,599, the HIMS's price is up by 1.72%, now at $37.92. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 21 days.</li>
</ul>
<h3>What The Experts Say On Hims &amp; Hers Health</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $28.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Sell, setting a price target of $25. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Hims &amp; Hers Health, targeting a price of $24. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Hims &amp; Hers Health with a target price of $31. 
&#x2A; In a cautious move, an analyst from BTIG downgraded its rating to Buy, setting a price target of $35. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Hims &amp; Hers Health with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Unusual Options Activity For February 03

Whales with a lot of money to spend have taken a noticeably bullish stance on Caterpillar.
Looking at options history for Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) we detected 28 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 28% with bearish.
From the overall spotted trades, 21 are puts, for a total amount of $869,588 and 7, calls, for a total amount of $284,563.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $350.0 and $390.0 for Caterpillar, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Caterpillar's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Caterpillar's substantial trades, within a strike price spectrum from $350.0 to $390.0 over the preceding 30 days.
<h3>Caterpillar Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738597550_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$4.95</td>
<td>$3.65</td>
<td>$4.95</td>
<td>$370.00</td>
<td>$97.5K</td>
<td>69</td>
<td align="right">89</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.15</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$350.00</td>
<td>$87.7K</td>
<td>2.0K</td>
<td align="right">962</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.3</td>
<td>$350.00</td>
<td>$75.9K</td>
<td>2.0K</td>
<td align="right">652</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$13.3</td>
<td>$11.7</td>
<td>$12.76</td>
<td>$370.00</td>
<td>$61.6K</td>
<td>248</td>
<td align="right">50</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$31.35</td>
<td>$30.65</td>
<td>$30.91</td>
<td>$390.00</td>
<td>$52.5K</td>
<td>2.7K</td>
<td align="right">190</td>
</tr>
</tbody>
</table>

<h3>About Caterpillar</h3>
Caterpillar is the world's leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Its reporting segments are: construction industries (40% sales/47% operating profit, or OP), resource industries (20% sales/19% OP), and energy &amp; transportation (40% sales/34% OP). Market share approaches 20% across many products. Caterpillar operates a captive finance subsidiary to facilitate sales. The firm has global reach (46% US sales/54% ex-US). Construction skews more domestic, while the other divisions are more geographically diversified. An independent network of 156 dealers operates approximately 2,800 facilities, giving Caterpillar reach into about 190 countries for sales and support services.
In light of the recent options history for Caterpillar, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Caterpillar's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 920,356, the CAT's price is down by -1.37%, now at $366.37. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 80 days.</li>
</ul>
<h3>Expert Opinions on Caterpillar</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $408.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Caterpillar with a target price of $490. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Caterpillar with a target price of $455. 
&#x2A; An analyst from UBS has elevated its stance to Neutral, setting a new price target at $385. 
&#x2A; An analyst from Morgan Stanley persists with their Underweight rating on Caterpillar, maintaining a target price of $300. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Caterpillar, which currently sits at a price target of $414. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Caterpillar with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Caterpillar's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $271,120 and 3, calls, for a total amount of $100,924.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $110.0 for Novo Nordisk over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Novo Nordisk stands at 1425.0, with a total volume reaching 5,628.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $65.0 to $110.0, throughout the last 30 days.
<h3>Novo Nordisk Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738597545_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.65</td>
<td>$83.00</td>
<td>$137.2K</td>
<td>374</td>
<td>377</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.17</td>
<td>$0.06</td>
<td>$0.1</td>
<td>$65.00</td>
<td>$45.0K</td>
<td>5.5K</td>
<td>5.0K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$84.00</td>
<td>$38.0K</td>
<td>125</td>
<td>103</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$2.36</td>
<td>$2.18</td>
<td>$2.37</td>
<td>$84.00</td>
<td>$35.5K</td>
<td>643</td>
<td>9</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$6.65</td>
<td>$6.55</td>
<td>$6.6</td>
<td>$77.00</td>
<td>$34.3K</td>
<td>10</td>
<td>52</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,627,289, the price of NVO is down by -1.71%, reaching $83.01.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 2 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity

Wells Fargo analyst Joseph O'Dea maintains Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with a Equal-Weight and lowers the price target from $350 to $335.

Wells Fargo Maintains Equal-Weight on Eaton Corp, Lowers Price Target to $335

No one can accuse Kevin Costner of not putting his money where his mouth is. However, as the veteran Hollywood actor has learned, passion projects can be a dangerous thing.
Costner was very vocal about his self-funded four-part Western drama Horizon and even quit the streaming hit <a href="https://www.benzinga.com/markets/24/12/42296924/montanas-housing-market-gets-crazy-with-85-jump-in-home-prices">Yellowstone</a> to film it. Horizon, however, tanked at the box office. Recent solid Netflix numbers have been an unexpected salvation, and now, according to Life &amp; Style, the Dances With Wolves star is hoping <a href="https://www.benzinga.com/content/43218115/netflix-stock-positioned-for-explosive-growth-in-2025">Netflix </a>will buy the entire series from him to recoup his losses. If not, he might be forced to part with some of his real estate holdings.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
<li>CEO of Integris gathered a team of senior investment managers who have $34.22 billion in combined owned and managed assets in the West Coast —<a href="https://www.benzinga.com/money/integris"> here&#8217;s how to invest in their private credit fund that targets 12% annual interest rate.</a></li>
</ul>
&#8220;I fit [Horizon] into the gaps,&#8221; Costner told<a href="https://deadline.com/2024/05/kevin-costner-horizon-an-american-saga-yellowstone-controversy-1235907679/"> </a>Deadline of his leaving Yellowstone. &#8220;They just kept moving their gaps.&#8221;
Despite hopes that Horizon might emulate the success of Yellowstone, box office numbers failed to materialize, leaving the acting icon in a deep financial hole.
<h2 class="wp-block-heading">Horizon&#8217;s High Stakes Gamble</h2>
&#8220;Kevin is good at projecting calm, experience, and a generally level head, but behind the scenes, the whole Horizon project has been stressful to him financially, physically, and even intellectually,&#8221; a source who has worked closely with Costner on the Western saga, was quoted as saying in Life &amp; Style.&nbsp;
Costner reportedly sunk $60 million of his own money into Horizon. However, after the first installment&#8217;s weak reception, the second installment didn&#8217;t even make it to theaters despite a warmer critical response from the festival circuit.
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/go/arrived-private-credit-yf">7-9% target yield with monthly dividends would you invest in it</a>?
After the success of the first Horizon on Netflix, which made it to the top 10, Costner and his team hope the streaming giant will pick up the remaining series and help recoup some of the money the actor poured into the project.&nbsp;
<h2 class="wp-block-heading">Netflix Cavalry To The Rescue</h2>
The insider quoted in Life &amp; Style feature revealed: &#8220;Netflix is the only company with deep enough pockets to completely bail him out of the hole Kevin has dug for himself with these movies. It&#8217;s a big check to write,&#8221; the insider continued &#8220;but if the first movie continues to perform well for Netflix&#8217;s viewers, the expectation around town and even within Kevin&#8217;s Hollywood circle is that Netflix will eventually step up and buy the rights to the whole series and take Kevin out of debt.&#8221;&nbsp;
<h2 class="wp-block-heading">Costner&#8217;s Real Estate Nest Egg</h2>
It&#8217;s not as if Costner sacrificed all his money for the Horizon project. According to court documents from his recent divorce — as revealed in<a href="https://www.benzinga.com/real-estate/24/12/42462666/plan-and-budget-for-the-mid-6-range-what-homebuyers-can-expect-in-2025-according-to-realtor-com"> realtor.com</a> — the actor has a substantial net worth of $400 million. He earned $1.3 million per episode for Yellowstone and used his considerable real estate holdings to bankroll Horizon.
Trending: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-y2">with $1,000 you can invest at just $0.26/share!</a>
One property in particular provided the funding—a spacious compound in Carpinteria, California, purchased in 1988. He and his first wife, Cindy Silva, lived there after marrying in 1978. They split in 1994. The property is estimated to be worth $145 million, and Coster took out a mortgage on the home to pay for Horizon.
The Carpinteria property, which sits on 1.4 acres of land, comprises a main house and two additional homes, all of which offer sweeping views of the Pacific Ocean. When Costner and Silva divorced, Costner took sole ownership of the home.&nbsp;
The property was thrown back into the spotlight during the actor&#8217;s most recent divorce from designer Christine Baumgartner last year when she refused to leave and moved into one of the smaller homes on the land. However, because Costner purchased the property before the two were married, his ex, according to standard divorce law, would not have a claim to his pre-marital assets. Eventually, Baumgartner did leave.
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.
<h2 class="wp-block-heading">Funding His Artistic Vision</h2>
In using his primary asset to fund a risky movie venture, Costner turned a deaf ear to his financial advisors. He told<a href="https://deadline.com/2023/05/francis-ford-coppola-kevin-costner-interview-megalopolis-horizon-1235359148/"> </a>Deadline at the time: &#8220;I&#8217;ve mortgaged 10 acres on the water in Santa Barbara where I was going to build my last house. But I did it without a thought. It has thrown my accountant into a f— conniption fit. But it&#8217;s my life, and I believe in the idea and the story.&#8221;
Costner&#8217;s other real estate jewel is his sprawling Aspen, Colorado, ranch. He and Baumgartner bought the property in 2000 for $300,000 and were married there in 2004. The vacation hot spot includes a lake, a baseball field, a sledding hill, and three hot tubs. Full-time staff keep the ranch in pristine condition, enabling it to be rented out for $36,000 a night and as much as $250,000 per week.
Though Costner&#8217;s romantic life and film career have undergone the same triumphs and pitfalls as many others in his business — his real estate holdings have undoubtedly been his best investment.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-y2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf"> </a></li>
</ul>

Real Estate

Kevin Costner Is Hoping Netflix Can Bail Him Out Of His Horizon Debt, Or He Might Have To Sell His $200M Property Portfolio

Politics

General

President Trump Agreed To Immediately Pause The Anticipated Tariffs For A One Month Period With Mexico's President; Says We Will Have Negotiations Headed By Rubio, Bessent, Howard Lutnick, And Mexican Officials, Says Look Forward To Participating In Those Negotiations With President Sheinbaum As We Attempt To Achieve A "Deal" Between Our Two Countries

RBC Capital analyst Brian Abrahams maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $139 to $143.

AXSM

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $143

Wells Fargo analyst Jason Haas maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Overweight and lowers the price target from $321 to $313.

Wells Fargo Maintains Overweight on Equifax, Lowers Price Target to $313

WIIM

ELUT

Elutia shares are trading lower after the company announced it secured a $15.6 million direct offering of 5.52 million shares.

The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) will release earnings results for its second quarter, after the <a href="https://www.benzinga.com/quote/CLX/earnings">closing bell on Monday, Feb. 3, 2025.</a>
Analysts expect the Oakland, California-based company to report quarterly earnings at $1.4 per share, down from $2.16 per share in the year-ago period. Clorox projects to report revenue of $1.63 billion for the recent quarter, compared to $1.99 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 28, The Clorox Company said that CFO Kevin Jacobsen will retire on April 1 after almost 30 years at the company.
Clorox shares fell 1.1% to close at $158.68 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Lauren Lieberman maintained an Underweight rating and cut the price target from $139 to $130 on Jan. 17, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Wells Fargo analyst Chris Carey upgraded the stock from Underweight to Equal-Weight and raised the price target from $155 to $157 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>TD Cowen analyst Robert Moskow upgraded the stock from Sell to Hold and raised the price target from $155 to $170 on Nov. 6, 2024. This analyst has an accuracy rate of 67%.</li>
<li>DA Davidson analyst Linda Bolton Weiser maintained a Neutral rating and boosted the price target from $153 to $171 on Nov. 4, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Citigroup analyst Wendy Nicholson maintained a Neutral rating and increased the price target from $165 to $170 on Sept. 6, 2024. This analyst has an accuracy rate of 64%.</li>
</ul>
Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1018" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1.png" alt="" class="wp-image-762185" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1.png 1018w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03045156/image-1-768x419.png 768w" sizes="(max-width: 1018px) 100vw, 1018px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Clorox Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

On Monday, Invivyd Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rallied on the heels of a new data report <a href="https://www.benzinga.com/topic/covid-19">involving a COVID-19 treatment</a>. 
The company is conducting an ongoing Phase 1/2 trial of VYD2311, a monoclonal antibody (mAb) candidate. A formal estimate of in vivo half-life is not yet available for VYD2311 given the long apparent half-life thus far.
As of Day 65, serum concentrations remain high, potentially substantially increasing the observed half-life of VYD2311 relative to pemivibart, the company&#8217;s&nbsp;monoclonal antibody&nbsp;medication authorized for the&nbsp;pre-exposure prophylaxis&nbsp;(prevention) of&nbsp;COVID‑19.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42920654/whats-going-on-with-covid-19-antibody-developer-invivyd-stock-on-friday" rel="noreferrer noopener">What&#8217;s Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?</a>
Analysis for the IM cohort (the most advanced cohort in time) is tracking generally with the PK profile of adintrevimab, a previous Invivyd mAb with an estimated in vivo half-life of 139 days.
PK analysis of VYD2311 intravenous and subcutaneous cohorts at earlier timepoints, at either similar doses subcutaneously or higher doses intravenously, are similarly and encouragingly tracking close to the estimated curves for adintrevimab thus far.
In vitro neutralization data generated continuously on VYD2311 as part of Invivyd&#8217;s industrial virology efforts demonstrate an average potency improvement for VYD2311 of approximately 17-fold compared to pemivibart.
The combined safety, pharmacokinetics (PK), and virology data for VYD2311, along with findings from Invivyd&#8217;s CANOPY Phase 3 trial and previous monoclonal antibody (mAb) studies, suggest that VYD2311 could offer strong and long-lasting protection against COVID-19.
A single dose may provide high protective antibody levels for six months to a year or longer.
The company also reported preliminary fourth quarter 2024 Pemgarda (pemivibart) net product revenue of $13.8 million. That&#8217;s 48% growth over Q3 2024 net product revenue of $9.3 million.
The company&#8217;s preliminary ending 2024 cash and cash <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43429956/invivyd-announces-preliminary-fourth-quarter-2024-financial-results-strong-revenue-growth-and-reit" rel="noreferrer noopener">equivalents of $69.3 million</a>.
Price Action: Invivyd stock is up 72.8% at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43432128/owens-minor-stock-dips-on-mixed-q4-preliminary-results-310-million-apria-goodwill-charge-details" target="_blank" rel="noreferrer noopener">Owens &amp; Minor Stock Dips On Mixed Q4 Preliminary Results &amp; $310 Million Apria Goodwill Charge: Details</a></li>
</ul>

Biotech

Health Care

IVVD

Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps

RBC Capital analyst Scott Heleniak maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Sector Perform and raises the price target from $390 to $400.

RBC Capital Maintains Sector Perform on Aon, Raises Price Target to $400

Splash Beverage Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#NYSE">SBEV</a>), an innovator in the beverage industry, proudly announces another 2024 retail expansion win. Total Wine &amp; More, America's Wine Superstore and the country's largest independent retailer of fine wine, has authorized Pulpoloco Sangria across multiple states. This authorization includes Pulpoloco' Smooth Red and Crisp White Sangria varietals and spans over 115 stores in Arizona, California, Colorado, Florida, Illinois, Nevada, Texas, and Virginia.
Known for its exceptional selection of fine wines, spirits, and variety, Total Wine &amp; More is a trusted destination for consumers seeking new and exciting beverage options. The addition of Pulpoloco Sangria to their shelves underscores the growing popularity and appeal of this innovative sangria brand, which combines authentic Spanish flavors with convenience and sustainability.

SBEV

Splash Beverage Group Expands Pulpoloco Sangria Distribution With Total Wine & More; Authorization Includes Pulpoloco' Smooth Red And Crisp White Sangria Varietals And Spans Over 115 Stores In Arizona, California, Colorado, Florida, Illinois, Nevada, Texas, And Virginia

U.S. stocks traded lower this morning, with the Nasdaq Composite dipping 1.5% on Monday.
Following the market opening Monday, the Dow traded down 0.63% to 44,262.92 while the NASDAQ dipped 1.50% to 19,334.02. The S&amp;P 500 also fell, dropping, 1.13% to 5,972.20.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Consumer staples shares surged by 0.4% on Monday.
In trading on Monday, information technology shares fell by 2%.
Top Headline
Tyson Foods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) posted better-than-expected first-quarter FY25 earnings result.
The company reported first-quarter FY25 sales growth of 2.3% year-on-year to $13.62 billion, beating the analyst consensus estimate of $13.44 billion.
Adjusted EBITDA for the quarter increased 29.2% to $961 million. Adjusted EPS of $1.14 beat the consensus estimate of $0.88.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 129% to $0.6377 after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>Shares of MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UOKA#NASDAQ">UOKA</a>)got a boost, surging 92% to $0.2490.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares were also up, gaining 78% to $18.82 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 55% to $0.1206.</li>
<li>Shares of Heramba Electric plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) were down 51% to $0.4324.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) was down, falling 46% to $0.2292. Tonix Pharmaceuticals announced a 1-for-100 reverse stock split, effective Feb. 5.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $72.26 while gold traded up 0.9% at $2,861.10.
Silver traded up 0.4% to $32.390 on Monday, while copper rose 0.1% to $4.2815.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.5%, Germany's DAX 40 dipped 2.1% and France's CAC 40 declined 1.9%. Spain's IBEX 35 Index fell 2.1%, while London's FTSE 100 fell 1.5%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 2.66%, Hong Kong's Hang Seng Index fell 0.04% and India's BSE Sensex falling 0.41%.
Economics
<ul>
<li>U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.</li>
<li>The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.</li>
<li>The S&amp;P Global manufacturing PMI rose to 51.2 in January, versus a preliminary reading of 50.1 and compared to 49.4 in December.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/02/43432854/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q4 Earnings</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

GHRS

HCWB

PITA

TNXP

UOKA

S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $195 to $210.

ABBV

Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $210

Wells Fargo analyst Elyse Greenspan maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $410 to $445.

Wells Fargo Maintains Overweight on Aon, Raises Price Target to $445

Rapid7, Tenable cut to Hold at Stifel on low priority of vulnerability management

Scotiabank analyst Patrick Colville raised the firm's price target on Tenable (TENB) to $45 from $44 and keeps a Sector Perform rating on the share...

Tenable price target raised to $45 from $44 at Scotiabank

Analysts, along with Eron Howard, COO at Novacoast and Jeremy Wittkop, Principal Enterprise Architect at Proofpoint, discuss quarterly industry and...

DA Davidson enterprise security analysts hold analyst/industry conference call

Tenable to acquire Vulcan Cyber for $147M in cash and $3M of restricted stock units

Tenable (TENB) announced that it has signed a definitive agreement to acquire Vulcan Cyber. Vulcan Cyber's capabilities will augment Tenable's indu...

Tenable plans to acquire Vulcan Cyber for $147M in cash, $3M in RSUs

Analyst Shrenik Kothari from Robert W. Baird maintained a Buy rating on Tenable Holdings (TENB – Research Report) and keeping the price target at $...

Tenable Holdings' Strategic Acquisitions Bolster Exposure Management and Cloud Security Capabilities

TD Cowen analyst Shaul Eyal reiterated a Buy rating on Tenable Holdings (TENB – Research Report) today and set a price target of $55.00. The compan...

Tenable Holdings (TENB) Receives a Rating Update from a Top Analyst

Tenable Holdings ( ($TENB) ) has issued an update. On January 29, 2025, Tenable Holdings announced a definitive agreement to acquire Vulcan Cyber L...

Tenable Holdings Acquires Vulcan Cyber for $150 Million

In a report released today, Patrick Colville from Scotiabank reiterated a Hold rating on Tenable Holdings (TENB – Research Report), with a price ta...

Comments

Tenable Holdings

空売り

Tenable Holdings (NASDAQ:TENB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル